Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?

Meeshanthini Dogan^1,2, Robert Philibert^1,2,3

¹Cardio Diagnostics Inc, Chicago, IL, USA.

²Department of Biomedical Engineering, University of Iowa, Iowa City, IA, USA.

³Department of Psychiatry, University of Iowa, Iowa City, IA, USA.

PubMed PMC DOI PDF

Abstract

Advances in DNA methylation and artificial intelligence have led to new methods for assessing risk and diagnosing coronary heart disease (CHD), the leading cause of death. However, whether these technologies can also be harnessed to generate new pharmacotherapeutic agents or monitor the effectiveness of new or existing CHD therapies is unknown. In this perspective, we review the development of car…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.